Lundbeck Looks For Assets Across Value Chain To Ride Storm

While the Danish pharma unveiled its best ever financial results, recently installed ceo Deborah Dunsire confirms to Scrip that the company needs to bolster its pipeline and portfolio with assets in all phases of the value chain.

concept graph brain wave EEG
Lundbeck Maintains Focus On Brain Diseases • Source: Shutterstock

It was not that long after Deborah Dunsire took hold of the reins at Lundbeck Inc. that she knew she had a tough job on her hands. Strategic cost-cutting decisions by the previous ceo Kare Schultz, he left to join Teva Pharmaceutical Industries Ltd., had steadied the ship financially but the impending loss of exclusivity of the company’s best-selling drug, Onfi, the epilepsy treatment, was always going to be a major challenge.

Barely two months into the role and the company revealed at the end of October that its most advanced clinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.